STAT3-IN-47
STAT3-IN-47 is an orally active STAT3 inhibitor. STAT3-IN-47 exhibits broad-spectrum anti-tumor activity against HeLa, HepG2, U87, and LN229 cells. STAT3-IN-47 suppresses STAT3 activation in vitro. STAT3-IN-47 can be used for the study of solid tumors, especially central nervous system (CNS) malignancies and hepatocellular carcinoma.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 2787548-58-5
- Formule: C15H8N4O3S
- Masse moléculaire:324.31
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
IC50 & Target
[1]|
STAT3 |
In Vitro
STAT3-IN-47 (Compound S1) (0.1-10 μM) exhibits broad-spectrum anti-tumor activity against HeLa, HepG2, U87, and LN229 cells, with IC50 values of 5.066 μM, 0.8089 μM, 1.970 μM, and 1.412 μM respectively[1].
STAT3-IN-47 (0.1-10 μM) suppresses STAT3 activation in a dose-dependent manner in HeLa, HepG2, U87, and LN229 cells[1].
STAT3-IN-47 (0.5-2 μM) inhibits EGF-induced STAT3 phosphorylation (Y705) in HeLa cells and dose-dependently suppresses IL-6-induced STAT3 phosphorylation (Y705) in HepG2, U87, LN229 cells[1].
STAT3-IN-47 downregulates stemness-associated genes (Nanog, Oct4, β-catenin) in Huh7, LN229, and HepG2 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Parmacokinetics
Chemical Information
-
CAS No. 2787548-58-5
-
Masse moléculaire 324.31
-
Formule C15H8N4O3S
-
SMILES
O=C(C1=C2OC(/C=N/N3C=NNC3=S)=C1)C4=C(C2=O)C=CC=C4
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
STAT3-IN-47 Related Classifications
HY-178140 Related Classifications
Powered by Bioz